Depression

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Jan 12, 2022

Braxia Scientific Kicks Off Clinical Trial; Lands $3 Million Private Placement

Jan 10, 2022

Ketamine Therapy Has The Potential To Thwart Suicidal Thoughts And Depression

Dec 30, 2021

The Highlights Of Cybin’s Year-End Summary And A Look Ahead At 2022

Dec 22, 2021

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application

Dec 15, 2021

Compass Pathways Reports COMP360 Progress

Dec 14, 2021

Novamind Opens New Clinic Focused On Substance Use Disorders, Offering Alternative To Residential Treatment

Dec 6, 2021

MindMed is Preparing for a Presentation at the Benzinga Global Small Cap Conference

Dec 2, 2021

COMPASS Pathways Announces Even More Positive Results From Its COMP360 Therapy

Dec 1, 2021

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360…

Dec 1, 2021